Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Otenaproxesul and COVID-19 Data
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(42)
•••
Comment by Rawrasauruson Aug 19, 2021 11:00am
142 Views
Post# 33730189

RE:Otenaproxesul and COVID-19 Data

RE:Otenaproxesul and COVID-19 Data

You're welcome. Lol Sorry if my questions were getting too hyper specific for people. I've been meaning to reach out to them for awhile about some of this stuff, but going through IR doesn't get me anywhere. For the last year, I couldn't figure out why that wasn't in the known pipeline given the research that inidicates it's effectiveness as both a preventative and treatment for Covid-19 and it's associated cytokine storms.

 

If anyone wants citations for the basis for anything I discussed, feel free to reach out to me. Also, mstrmnd, you're an MD, yeah? You're one of the only people on here that seems to grasp the pharmakokinetics of otena so I've been wanting to pick your brain/share thoughts for awhile.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities